Your browser doesn't support javascript.
loading
Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP).
Steinbeis, Fridolin; Thibeault, Charlotte; Steinbrecher, Sarah; Ahlgrimm, Yvonne; Haack, Ira An; August, Dietrich; Balzuweit, Beate; Bellinghausen, Carla; Berger, Sarah; Chaplinskaya-Sobol, Irina; Cornely, Oliver; Doeblin, Patrick; Endres, Matthias; Fink, Claudia; Finke, Carsten; Frank, Sandra; Hanß, Sabine; Hartung, Tim; Hellmuth, Johannes Christian; Herold, Susanne; Heuschmann, Peter; Heyckendorf, Jan; Heyder, Ralf; Hippenstiel, Stefan; Hoffmann, Wolfgang; Kelle, Sebastian Ulrich; Knape, Philipp; Koehler, Philipp; Kretzler, Lucie; Leistner, David Manuel; Lienau, Jasmin; Lorbeer, Roberto; Lorenz-Depiereux, Bettina; Lüttke, Constanze Dorothea; Mai, Knut; Merle, Uta; Meyer-Arndt, Lil Antonia; Miljukov, Olga; Muenchhoff, Maximilian; Müller-Plathe, Moritz; Neuhann, Julia; Neuhauser, Hannelore; Nieters, Alexandra; Otte, Christian; Pape, Daniel; Pinto, Rafaela Maria; Pley, Christina; Pudszuhn, Annett; Reuken, Philipp; Rieg, Siegberg.
Afiliación
  • Steinbeis F; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Thibeault C; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Steinbrecher S; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Ahlgrimm Y; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Haack IA; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • August D; Division of Infectious Diseases, Department of Medicine II, Faculty of Medicine, Medical Centre-University of Freiburg, Freiburg, Germany.
  • Balzuweit B; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Bellinghausen C; Department of Respiratory Medicine/Allergology, Medical Clinic 1, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Berger S; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Chaplinskaya-Sobol I; Department of Medical Informatics, University Medical Center Göttingen, Göttingen, Germany.
  • Cornely O; Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
  • Doeblin P; Faculty of Medicine, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany.
  • Endres M; Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Berlin, Germany.
  • Fink C; Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Finke C; Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Frank S; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Hanß S; Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Hartung T; Department of Anesthesiology, University Hospital of Ludwig-Maximilians-University (LMU), Munich, Germany.
  • Hellmuth JC; Department of Medical Informatics, University Medical Center Göttingen, Göttingen, Germany.
  • Herold S; Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Heuschmann P; Department of Medicine III, University Hospital of Ludwig-Maximilians-University (LMU), Munich, Germany.
  • Heyckendorf J; COVID-19 Registry of the LMU Munich (CORKUM), University Hospital of Ludwig-Maximilians-University (LMU), Munich, Germany.
  • Heyder R; Department of Medicine V, Internal Medicine, Infectious Diseases and Infection Control, University Hospital Giessen and Marburg, Giessen, Germany.
  • Hippenstiel S; German Center for Lung Research (DZL), Institute of Lung Health (ILH), Excellence Cluster Cardiopulmonary Institute (CPI), Justus Liebig-University, Giessen, Germany.
  • Hoffmann W; Institute of Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany.
  • Kelle SU; Clinical Trial Center, Institute for Medical Data Science, University Hospital Würzburg, Würzburg, Germany.
  • Knape P; Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Koehler P; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, NUM Coordination Office, Berlin, Germany.
  • Kretzler L; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Leistner DM; Institute for Community Medicine Section Health Care Epidemiology and Community Health, University Medicine Greifswald, Greifswald, Germany.
  • Lienau J; Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Berlin, Germany.
  • Lorbeer R; Deutsches Herzzentrum der Charité, Klinik für Kardiologie, Angiologie und Intensivmedizin, Berlin, Germany.
  • Lorenz-Depiereux B; Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
  • Lüttke CD; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Mai K; Department of Cardiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Merle U; Department of Cardiology and Angiology, Goethe University Frankfurt, Frankfurt, Germany.
  • Meyer-Arndt LA; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Miljukov O; Institute of Computer-Assisted Cardiovascular Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany.
  • Muenchhoff M; Department of Radiology, University Hospital of Ludwig-Maximilians-University (LMU), Munich, Germany.
  • Müller-Plathe M; Institute of Epidemiology, Helmholtz Center Munich, Munich, Germany.
  • Neuhann J; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Neuhauser H; Department of Endocrinology and Metabolism, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Nieters A; German Center for Diabetes Research, Munich-Neuherberg, Germany.
  • Otte C; Department of Internal Medicine IVM, University Hospital Heidelberg, Heidelberg, Germany.
  • Pape D; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Pinto RM; Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Pley C; Institute of Clinical Epidemiology and Biometry, University Würzburg, Würzburg, Germany.
  • Pudszuhn A; Max Von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Ludwig-Maximilians-University Munich (LMU), Munich, Germany.
  • Reuken P; German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
  • Rieg S; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Infection ; 52(1): 93-104, 2024 Feb.
Article en En | MEDLINE | ID: mdl-37434025
ABSTRACT

BACKGROUND:

The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic causes a high burden of acute and long-term morbidity and mortality worldwide despite global efforts in containment, prophylaxis, and therapy. With unprecedented speed, the global scientific community has generated pivotal insights into the pathogen and the host response evoked by the infection. However, deeper characterization of the pathophysiology and pathology remains a high priority to reduce morbidity and mortality of coronavirus disease 2019 (COVID-19).

METHODS:

NAPKON-HAP is a multi-centered prospective observational study with a long-term follow-up phase of up to 36 months post-SARS-CoV-2 infection. It constitutes a central platform for harmonized data and biospecimen for interdisciplinary characterization of acute SARS-CoV-2 infection and long-term outcomes of diverging disease severities of hospitalized patients.

RESULTS:

Primary outcome measures include clinical scores and quality of life assessment captured during hospitalization and at outpatient follow-up visits to assess acute and chronic morbidity. Secondary measures include results of biomolecular and immunological investigations and assessment of organ-specific involvement during and post-COVID-19 infection. NAPKON-HAP constitutes a national platform to provide accessibility and usability of the comprehensive data and biospecimen collection to global research.

CONCLUSION:

NAPKON-HAP establishes a platform with standardized high-resolution data and biospecimen collection of hospitalized COVID-19 patients of different disease severities in Germany. With this study, we will add significant scientific insights and provide high-quality data to aid researchers to investigate COVID-19 pathophysiology, pathology, and chronic morbidity.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Observational_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Infection Año: 2024 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Observational_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Infection Año: 2024 Tipo del documento: Article País de afiliación: Alemania